Patents by Inventor Francesco G. Salituro

Francesco G. Salituro has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20200002371
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, and R6, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: July 7, 2017
    Publication date: January 2, 2020
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin, Daniel La
  • OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20190359646
    Abstract: Compounds are provided according to Formula (III) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R5, and n are as defined herein, and at least one hydrogen is replaced with a deuterium. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 28, 2019
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro
  • NEUROACTIVE STEROID SOLUTIONS AND THEIR METHODS OF USE
    Publication number: 20190350944
    Abstract: Provided herein are pharmaceutically acceptable aqueous solution comprising a neuroactive steroid, a sulfobutyl ether beta cyclodextrin and a buffer; wherein: the solution is a stable solution between a pH of about 3 and about 9, e.g., at room temperature, for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more; the buffer is present at a concentration of at least 0.1 mM; or the solution remains substantially free of impurities (e.g., the solution is substantially free of impurities at room temperature for at least 1, 2, 3, 4 weeks; 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months; 1, 2, 3 years or more).
    Type: Application
    Filed: May 28, 2019
    Publication date: November 21, 2019
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Paul Steven Watson, William Hunke
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20190345109
    Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Application
    Filed: January 9, 2019
    Publication date: November 14, 2019
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20190330259
    Abstract: Compounds are provided according to Formula (I), and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein A, R1, and R5 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: March 31, 2017
    Publication date: October 31, 2019
    Applicants: Sage Therapeutics, Inc., Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Francesco G. Salituro, Gabriel Martinez Botella, Boyd L. Harrison, John Gregory Reid
  • 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
    Patent number: 10435431
    Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I) and (III): where R1, R2, R3, R3?, R4, R6a, R6a, R11a, and R11b are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, insomnia, anxiety, depression, traumatic brain injury (TBI), stress, and epilepsy.
    Type: Grant
    Filed: August 21, 2017
    Date of Patent: October 8, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Ravindra B. Upasani, Benny C. Askew, Boyd L. Harrison, Francesco G. Salituro, Albert J. Robichaud
  • Compositions and methods for treating CNS disorders
    Patent number: 10426837
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, and R3 are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use, e.g., for treating a subject suffering from a disease or disorder described herein.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: October 1, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert J. Robichaud, Gabriel Martinez Botella, Francesco G. Salituro, Boyd L. Harrison
  • Glutaminase inhibitors and method of use
    Patent number: 10414740
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: June 4, 2018
    Date of Patent: September 17, 2019
    Assignee: Agios Pharmaceuticals, Inc.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan
  • 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
    Patent number: 10391106
    Abstract: Provided herein are 19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, and R4b are as defined herein, and A is a carbon bound substituted or unsubstituted 5- to 6-membered heteroaryl ring as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: August 27, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert J. Robichaud, Francesco G. Salituro, Richard T. Beresis
  • OXYSTEROLS AND METHODS OF USE THEREOF
    Publication number: 20190248829
    Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R2, R3, R4, R5, and and R6 are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
    Type: Application
    Filed: October 18, 2017
    Publication date: August 15, 2019
    Applicant: Sage Therapeutics, Inc.
    Inventors: Francesco G. Salituro, Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Andrew Griffin
  • C17, C20, AND C21 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
    Publication number: 20190248831
    Abstract: Described herein are neuroactive steroids or a pharmaceutically acceptable salt thereof. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
    Type: Application
    Filed: July 11, 2017
    Publication date: August 15, 2019
    Applicant: Sage Therapeutics, Inc.
    Inventors: Albert Jean ROBICHAUD, Gabriel MARTINEZ BOTELLA, Boyd L. HARRISON, Francesco G. SALITURO, Andrew GRIFFIN, Maria Jesus BLANCO-PILLADO
  • 19-nor neuroactive steroids and methods of use thereof
    Patent number: 10377790
    Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: August 13, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • THERAPEUTIC COMPOUNDS AND COMPOSITIONS
    Publication number: 20190241523
    Abstract: Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer.
    Type: Application
    Filed: June 18, 2018
    Publication date: August 8, 2019
    Inventors: Francesco G. Salituro, Jeffrey O. Saunders, Shunqi Yan
  • C7, C12, AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND THEIR METHODS OF USE
    Publication number: 20190233465
    Abstract: Described herein are neuroactive steroids of Formula (I), Formula (V), or Formula (IX) or a pharmaceutically acceptable salt thereof; wherein each instance of R2, R3, R4, R5, R6, R7, R11a, R11b, R12, R16, R17, R19, and are as herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such as for inducing sedation and/or anesthesia.
    Type: Application
    Filed: July 11, 2017
    Publication date: August 1, 2019
    Applicant: Sage Therapeutics, Inc.
    Inventors: Albert Jean Robichaud, Gabriel Martinez Botella, Boyd L. Harrison, Francesco G. Salituro, Andrew Griffin, Maria Jesus Blanco-Pillado
  • 19-NOR NEUROACTIVE STEROIDS AND METHODS OF USE THEREOF
    Publication number: 20190211054
    Abstract: Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (1): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, tinnitus, and status epilepticus.
    Type: Application
    Filed: April 29, 2016
    Publication date: July 11, 2019
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
    Patent number: 10342810
    Abstract: Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein , R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7 are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Grant
    Filed: June 27, 2018
    Date of Patent: July 9, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert Jean Robichaud, Francesco G. Salituro, Richard Thomas Beresis
  • Neuroactive steroids, compositions, and uses thereof
    Patent number: 10329320
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein R1, R2, Ra, G, X, Y, Z, and n are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. Also provided are pharmaceutical compositions comprising a compound described herein and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: February 19, 2016
    Date of Patent: June 25, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Albert J. Robichaud, Francesco G. Salituro, Boyd L. Harrison, Gabriel Martinez Botella
  • Neuroactive steroids, compositions, and uses thereof
    Patent number: 10323059
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Grant
    Filed: September 7, 2017
    Date of Patent: June 18, 2019
    Assignee: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Boyd L. Harrison, Albert J. Robichaud, Francesco G. Salituro
  • COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS
    Publication number: 20190177358
    Abstract: Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein , A, R1, R2, R3a, R4a, R4b, R5, R7a, and R7b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia.
    Type: Application
    Filed: November 30, 2018
    Publication date: June 13, 2019
    Applicant: Sage Therapeutics, Inc.
    Inventors: Gabriel Martinez Botella, Francesco G. Salituro, Albert Jean Robichaud, Boyd L. Harrison
  • NEUROACTIVE STEROIDS, COMPOSITIONS, AND USES THEREOF
    Publication number: 20190169226
    Abstract: Described herein are steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and/or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and/or withdrawal syndromes, and tinnitus.
    Type: Application
    Filed: February 7, 2019
    Publication date: June 6, 2019
    Inventors: Boyd L. Harrison, Gabriel Martinez Botella, Albert Jean Robichaud, Francesco G. Salituro